Genetic diseases of sphingolipid metabolism: Pathological mechanisms and therapeutic options

FEBS Letters

Volumn 580, Issue 23, 2006, Pages 5510-5517

  Kacher, Yaacov ^a   Futerman, Anthony H ^a  

^a WEIZMANN INSTITUTE OF SCIENCE   (Israel)

Author keywords

Calcium; Gangliosides; Glycosphingolipids; Lysosomal storage diseases; Sphingolipids; Therapy; Unfolded protein response

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; IMIGLUCERASE; MIGLUSTAT; SPHINGOLIPID;

ALZHEIMER DISEASE; APOPTOSIS; CALCIUM HOMEOSTASIS; CLINICAL TRIAL; ENZYME REPLACEMENT; ENZYME THERAPY; GAUCHER DISEASE; GENE THERAPY; GENETIC DISORDER; HUMAN; INFLAMMATION; LIPID DEGRADATION; LIPID METABOLISM; LIPIDOSIS; LIPOGENESIS; NEUROLOGIC DISEASE; NEUROTOXICITY; NONHUMAN; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN EXPRESSION; SHORT SURVEY; SIGNAL TRANSDUCTION; STATISTICAL SIGNIFICANCE; TAY SACHS DISEASE; TREATMENT OUTCOME;

ANIMALS; CALCIUM; ENDOPLASMIC RETICULUM; HUMANS; INFLAMMATION; METABOLIC DISEASES; SPHINGOLIPIDS; SUBSTRATE SPECIFICITY;

EID: 33749062163     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2006.08.041     Document Type: Short Survey

References (86)

1. Futerman A.H., and Hannun Y.A. The complex life of simple sphingolipids. EMBO Reps. 5 (2004) 777-782
2. Hannun Y.A., and Obeid L.M. The ceramide-centric universe of lipid-mediated cell regulation: stress encounters of the lipid kind. J. Biol. Chem. 277 (2002) 25847-25850
3. Merrill Jr. A.H. De novo sphingolipid biosynthesis. A necessary, but dangerous, pathway. J. Biol. Chem. 277 (2002) 25843-25846
4. Futerman A.H., and van Meer G. The cell biology of lysosomal storage disorders. Nat. Rev. Mol. Cell Biol. 5 (2004) 554-565
5. Simpson M.A., Cross H., Proukakis C., Priestman D.A., Neville D.C., Reinkensmeier G., Wang H., Wiznitzer M., Gurtz K., Verganelaki A., Pryde A., Patton M.A., Dwek R.A., Butters T.D., Platt F.M., and Crosby A.H. Infantile-onset symptomatic epilepsy syndrome caused by a homozygous loss-of-function mutation of GM3 synthase. Nat. Genet. 36 (2004) 1225-1229
6. Yamashita T., Hashiramoto A., Haluzik M., Mizukami H., Beck S., Norton A., Kono M., Tsuji S., Daniotti J.L., Werth N., Sandhoff R., Sandhoff K., and Proia R.L. Enhanced insulin sensitivity in mice lacking ganglioside GM3. Proc. Natl. Acad. Sci. USA 100 (2003) 3445-3449
7. Yamashita T., Wu Y.P., Sandhoff R., Werth N., Mizukami H., Ellis J.M., Dupree J.L., Geyer R., Sandhoff K., and Proia R.L. Interruption of ganglioside synthesis produces central nervous system degeneration and altered axon-glial interactions. Proc. Natl. Acad. Sci. USA 102 (2005) 2725-2730
8. Schwarz A., and Futerman A.H. The localization of gangliosides in neurons of the central nervous system: the use of anti-ganglioside antibodies. Biochim. Biophys. Acta 1286 (1996) 247-267
9. Yamashita T., Wada R., Sasaki T., Deng C., Bierfreund U., Sandhoff K., and Proia R.L. A vital role for glycosphingolipid synthesis during development and differentiation. Proc. Natl. Acad. Sci. USA 96 (1999) 9142-9147
10. Jennemann R., Sandhoff R., Wang S., Kiss E., Gretz N., Zuliani C., Martin-Villalba A., Jager R., Schorle H., Kenzelmann M., Bonrouhi M., Wiegandt H., and Grone H.J. Cell-specific deletion of glucosylceramide synthase in brain leads to severe neural defects after birth. Proc. Natl. Acad. Sci. USA 102 (2005) 12459-12464
11. Schwarz A., and Futerman A.H. Distinct roles for ceramide and glucosylceramide at different stages of neuronal growth. J. Neurosci. 17 (1997) 2929-2938
12. Schwarz A., and Futerman A.H. Inhibition of sphingolipid synthesis, but not degradation, alters the rate of dendrite growth in cultured hippocampal neurons. Brain Res. Dev. Brain Res. 108 (1998) 125-130
13. Boldin S.A., and Futerman A.H. Up-regulation of glucosylceramide synthesis upon stimulation of axonal growth by basic fibroblast growth factor. Evidence for post- translational modification of glucosylceramide synthase. J. Biol. Chem. 275 (2000) 9905-9909
14. Pewzner-Jung Y., Ben-Dor S., and Futerman A.H. When do lasses (longevity assurance genes) become CerS (ceramide synthases)? Insights into the regulation of ceramide synthesis. J. Biol. Chem. 281 (2006) 25001-25005
15. Koybasi S., Senkal C.E., Sundararaj K., Spassieva S., Bielawski J., Osta W., Day T.A., Jiang J.C., Jazwinski S.M., Hannun Y.A., Obeid L.M., and Ogretmen B. Defects in cell growth regulation by C18:0-ceramide and longevity assurance gene 1 in human head and neck squamous cell carcinomas. J. Biol. Chem. 279 (2004) 44311-44319
16. Futerman A.H., and Riezman H. The ins and outs of sphingolipid synthesis. Trends Cell Biol. 15 (2005) 312-318
17. Walkley S.U. Secondary accumulation of gangliosides in lysosomal storage disorders. Semin. Cell Dev. Biol. 15 (2004) 433-444
18. Conzelmann E., and Sandhoff K. Partial enzyme deficiencies: residual activities and the development of neurological disorders. Dev. Neurosci. 6 (1983) 58-71
19. Raas-Rothschild A., Pankova-Kholmyansky I., Kacher Y., and Futerman A.H. Glycosphingolipidoses: beyond the enzymatic defect. Glycoconj. J. 21 (2004) 295-304
20. Petersen G.M., Rotter J.I., Cantor R.M., Field L.L., Greenwald S., Lim J.S., Roy C., Schoenfeld V., Lowden J.A., and Kaback M.M. The Tay-Sachs disease gene in North American Jewish populations: geographic variations and origin. Am. J. Hum. Genet. 35 (1983) 1258-1269
21. Meikle P.J., Hopwood J.J., Clague A.E., and Carey W.F. Prevalence of lysosomal storage disorders. Jama 281 (1999) 249-254
22. Meikle P.J., and Hopwood J.J. Lysosomal storage disorders: emerging therapeutic options require early diagnosis. Eur. J. Pediatr. 162 Suppl. 1 (2003) S34-S37
23. Chen C.S., Patterson M.C., Wheatley C.L., O'Brien J.F., and Pagano R.E. Broad screening test for sphingolipid-storage diseases. Lancet 354 (1999) 901-905
24. Sillence D.J., and Platt F.M. Glycosphingolipids in endocytic membrane transport. Semin. Cell Dev. Biol. 15 (2004) 409-416
25. Marks D.L., and Pagano R.E. Endocytosis and sorting of glycosphingolipids in sphingolipid storage disease. Trends Cell Biol. 12 (2002) 605-613
26. Sillence D.J., and Platt F.M. Storage diseases: new insights into sphingolipid functions. Trends Cell Biol. 13 (2003) 195-203
27. Puri V., Watanabe R., Dominguez M., Sun X., Wheatley C.L., Marks D.L., and Pagano R.E. Cholesterol modulates membrane traffic along the endocytic pathway in sphingolipid-storage diseases. Nat. Cell Biol. 1 (1999) 386-388
28. Choudhury A., Dominguez M., Puri V., Sharma D.K., Narita K., Wheatley C.L., Marks D.L., and Pagano R.E. Rab proteins mediate Golgi transport of caveola-internalized glycosphingolipids and correct lipid trafficking in Niemann-Pick C cells. J. Clin. Invest 109 (2002) 1541-1550
29. Brown D.A., and London E. Structure and function of sphingolipid- and cholesterol-rich membrane rafts. J. Biol. Chem. 275 (2000) 17221-17224
30. Cheng Z.J., Singh R.D., Sharma D.K., Holicky E.L., Hanada K., Marks D.L., and Pagano R.E. Distinct mechanisms of clathrin-independent endocytosis have unique sphingolipid requirements. Mol. Biol Cell. 17 (2006) 3197-3210
31. Jeyakumar M., Thomas R., Elliot-Smith E., Smith D.A., van der Spoel A.C., d'Azzo A., Perry V.H., Butters T.D., Dwek R.A., and Platt F.M. Central nervous system inflammation is a hallmark of pathogenesis in mouse models of GM1 and GM2 gangliosidosis. Brain 126 (2003) 974-987
32. Myerowitz R., Lawson D., Mizukami H., Mi Y., Tifft C.J., and Proia R.L. Molecular pathophysiology in Tay-Sachs and Sandhoff diseases as revealed by gene expression profiling. Hum. Mol. Genet. 11 (2002) 1343-1350
33. Wada R., Tifft C.J., and Proia R.L. Microglial activation precedes acute neurodegeneration in Sandhoff disease and is suppressed by bone marrow transplantation. Proc. Natl. Acad. Sci. USA 97 (2000) 10954-10959
34. Baudry M., Yao Y., Simmons D., Liu J., and Bi X. Postnatal development of inflammation in a murine model of Niemann-Pick type C disease: immunohistochemical observations of microglia and astroglia. Exp. Neurol. 184 (2003) 887-903
35. Jmoudiak M., and Futerman A.H. Gaucher disease: pathological mechanisms and modern management. Br. J. Haematol. 129 (2005) 178-188
36. Barak V., Acker M., Nisman B., Kalickman I., Abrahamov A., Zimran A., and Yatziv S. Cytokines in Gaucher's disease. Eur. Cytokine Network 10 (1999) 205-210
37. Hollak C.E., Evers L., Aerts J.M., and van Oers M.H. Elevated levels of M-CSF, sCD14 and IL8 in type 1 Gaucher disease. Blood Cells, Mol. Dis. 23 (1997) 201-212
38. Boven L.A., van Meurs M., Boot R.G., Mehta A., Boon L., Aerts J.M., and Laman J.D. Gaucher cells demonstrate a distinct macrophage phenotype and resemble alternatively activated macrophages. Am. J. Clin. Pathol. 122 (2004) 359-369
39. Korhonen R., Kankaanranta H., Lahti A., Lahde M., Knowles R.G., and Moilanen E. Bi-directional effects of the elevation of intracellular calcium on the expression of inducible nitric oxide synthase in J774 macrophages exposed to low and to high concentrations of endotoxin. Biochem. J. 354 (2001) 351-358
40. Verkhratsky A. The endoplasmic reticulum and neuronal calcium signalling. Cell Calcium 32 (2002) 393-404
41. Berridge M.J., Bootman M.D., and Roderick H.L. Calcium signalling: dynamics, homeostasis and remodelling. Nat. Rev. Mol. Cell Biol. 4 (2003) 517-529
42. Stefani A., Spadoni F., and Bernardi G. Voltage-activated calcium channels: targets of antiepileptic drug therapy?. Epilepsia 38 (1997) 959-965
43. Small D.L., Morley P., and Buchan A.M. Biology of ischemic cerebral cell death. Prog. Cardiovasc. Dis. 42 (1999) 185-207
44. Mattson M.P., and Chan S.L. Neuronal and glial calcium signaling in Alzheimer's disease. Cell Calcium 34 (2003) 385-397
45. Bodennec J., Pelled D., Riebeling C., Trajkovic S., and Futerman A.H. Phosphatidylcholine synthesis is elevated in neuronal models of Gaucher disease due to direct activation of CTP:phosphocholine cytidylyltransferase by glucosylceramide. Faseb J. 16 (2002) 1814-1816
46. Sango K., Yamanaka S., Hoffmann A., Okuda Y., Grinberg A., Westphal H., McDonald M.P., Crawley J.N., Sandhoff K., Suzuki K., and Proia R.L. Mouse models of Tay-Sachs and Sandhoff diseases differ in neurologic phenotype and ganglioside metabolism. Nat. Genet. 11 (1995) 170-176
47. 2+-ATPase in a mouse model of Sandhoff disease and prevention by treatment with N-butyldeoxynojirimycin. J. Biol. Chem. 278 (2003) 29496-29501
48. Ginzburg L., and Futerman A.H. Defective calcium homeostasis in the cerebellum in a mouse model of Niemann-Pick A disease. J. Neurochem. 95 (2005) 1619-1628
49. Tessitore A., del P.M.M., Sano R., Ma Y., Mann L., Ingrassia A., Laywell E.D., Steindler D.A., Hendershot L.M., and d'Azzo A. GM1-ganglioside-mediated activation of the unfolded protein response causes neuronal death in a neurodegenerative gangliosidosis. Mol. Cell 15 (2004) 753-766
50. Breckenridge D.G., Germain M., Mathai J.P., Nguyen M., and Shore G.C. Regulation of apoptosis by endoplasmic reticulum pathways. Oncogene 22 (2003) 8608-8618
51. Feng B., Yao P.M., Li Y., Devlin C.M., Zhang D., Harding H.P., Sweeney M., Rong J.X., Kuriakose G., Fisher E.A., Marks A.R., Ron D., and Tabas I. The endoplasmic reticulum is the site of cholesterol-induced cytotoxicity in macrophages. Nat. Cell Biol. 5 (2003) 781-792
52. Rutkowski D.T., and Kaufman R.J. A trip to the ER: coping with stress. Trends Cell Biol. 14 (2004) 20-28
53. Kaneko M., and Nomura Y. ER signaling in unfolded protein response. Life Sci. 74 (2003) 199-205
54. Paschen W., and Mengesdorf T. Endoplasmic reticulum stress response and neurodegeneration. Cell Calcium 38 (2005) 409-415
55. Yuan J., and Yankner B.A. Apoptosis in the nervous system. Nature 407 (2000) 802-809
56. Zhang K., and Kaufman R.J. The unfolded protein response: a stress signaling pathway critical for health and disease. Neurology 66 (2006) S102-S109
57. Kim S.J., Zhang Z., Hitomi E., Lee Y.C., and Mukherjee A.B. Endoplasmic reticulum stress-induced caspase-4 activation mediates apoptosis and neurodegeneration in INCL. Hum. Mol. Genet. 15 (2006) 1826-1834
58. Sriburi R., Jackowski S., Mori K., and Brewer J.W. XBP1: a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. J. Cell Biol. 167 (2004) 35-41
59. Cui Z., and Houweling M. Phosphatidylcholine and cell death. Biochim. Biophys. Acta 1585 (2002) 87-96
60. Jackowski S. Coordination of membrane phospholipid synthesis with the cell cycle. J. Biol. Chem. 269 (1994) 3858-3867
61. Futerman A.H., and Banker G.A. The economics of neurite outgrowth-the addition of new membrane to growing axons. Trends Neurosci. 19 (1996) 144-149
62. Takei K., Shin R.M., Inoue T., Kato K., and Mikoshiba K. Regulation of nerve growth mediated by inositol 1,4,5-trisphosphate receptors in growth cones. Science 282 (1998) 1705-1708
63. 2+ induce the dedifferentiation of axonal segments into growth cones. J. Neurosci. 17 (1997) 3568-3579
64. Walkley S.U., Zervas M., and Wiseman S. Gangliosides as modulators of dendritogenesis in normal and storage disease-affected pyramidal neurons. Cereb. Cortex 10 (2000) 1028-1037
65. 2+ mobilization with thapsigargin reduces neurite initiation in cultured adult rat DRG neurons. Brain Res. Dev. Brain Res. 84 (1995) 151-163
66. Schwarz A., Rapaport E., Hirschberg K., and Futerman A.H. A regulatory role for sphingolipids in neuronal growth. Inhibition of sphingolipid synthesis and degradation have opposite effects on axonal branching. J. Biol. Chem. 270 (1995) 10990-10998
67. Tybulewicz V.L., Tremblay M.L., LaMarca M.E., Willemsen R., Stubblefield B.K., Winfield S., Zablocka B., Sidransky E., Martin B.M., Huang S.P., et al. Animal model of Gaucher's disease from targeted disruption of the mouse glucocerebrosidase gene. Nature 357 (1992) 407-410
68. Pelled D., Riebeling C., van Echten-Deckert G., Sandhoff K., and Futerman A.H. Reduced rates of axonal and dendritic growth in embryonic hippocampal neurones cultured from a mouse model of Sandhoff disease. Neuropathol. Appl. Neurobiol. 29 (2003) 341-349
69. Buccoliero R., Bodennec J., Van Echten-Deckert G., Sandhoff K., and Futerman A.H. Phospholipid synthesis is decreased in neuronal tissue in a mouse model of Sandhoff disease. J. Neurochem. 90 (2004) 80-88
70. Trajkovic-Bodennec S., Bodennec J., and Futerman A.H. Phosphatidylcholine metabolism is altered in a monocyte-derived macrophage model of Gaucher disease but not in lymphocytes. Blood Cells Mol. Dis. 33 (2004) 77-82
71. Ginzburg L., Kacher Y., and Futerman A.H. The pathogenesis of glycosphingolipid storage disorders. Semin. Cell Dev. Biol. 15 (2004) 417-431
72. Futerman A.H., Sussman J.L., Horowitz M., Silman I., and Zimran A. New directions in the treatment of Gaucher disease. Trends Pharmacol. Sci. 25 (2004) 147-151
73. Dvir H., Harel M., McCarthy A.A., Toker L., Silman I., Futerman A.H., and Sussman J.L. X-ray structure of human acid-beta-glucosidase, the defective enzyme in Gaucher disease. EMBO Rep. 4 (2003) 704-709
74. Desnick R.J., and Schuchman E.H. Enzyme replacement and enhancement therapies: lessons from lysosomal disorders. Nat. Rev. Genet. 3 (2002) 954-966
75. Vogler C., Levy B., Grubb J.H., Galvin N., Tan Y., Kakkis E., Pavloff N., and Sly W.S. Overcoming the blood-brain barrier with high-dose enzyme replacement therapy in murine mucopolysaccharidosis VII. Proc. Natl. Acad. Sci. USA 102 (2005) 14777-14782
76. Cox T.M., Aerts J.M., Andria G., Beck M., Belmatoug N., Bembi B., Chertkoff R., Vom Dahl S., Elstein D., Erikson A., Giralt M., Heitner R., Hollak C., Hrebicek M., Lewis S., Mehta A., Pastores G.M., Rolfs A., Miranda M.C., and Zimran A. The role of the iminosugar N-butyldeoxynojirimycin (miglustat) in the management of type I (non-neuronopathic) Gaucher disease: a position statement. J. Inherit. Metab. Dis. 26 (2003) 513-526
77. Lachmann R.H. Miglustat. Oxford glycosciences/actelion. Curr. Opin. Investig. Drugs 4 (2003) 472-479
78. Cox T., Lachmann R., Hollak C., Aerts J., van Weely S., Hrebicek M., Platt F., Butters T., Dwek R., Moyses C., Gow I., Elstein D., and Zimran A. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis. Lancet 355 (2000) 1481-1485
79. Platt F.M., Neises G.R., Reinkensmeier G., Townsend M.J., Perry V.H., Proia R.L., Winchester B., Dwek R.A., and Butters T.D. Prevention of lysosomal storage in Tay-Sachs mice treated with N-butyldeoxynojirimycin. Science 276 (1997) 428-431
80. Buccoliero R., and Futerman A.H. The roles of ceramide and complex sphingolipids in neuronal cell function. Pharmacol. Res. 47 (2003) 409-419
81. Fan J.Q. A contradictory treatment for lysosomal storage disorders: inhibitors enhance mutant enzyme activity. Trends Pharmacol. Sci. 24 (2003) 355-360
82. Desnick R.J. Enzyme replacement and enhancement therapies for lysosomal diseases. J. Inherit. Metab. Dis. 27 (2004) 385-410
83. Pastores G.M., and Barnett N.L. Current and emerging therapies for the lysosomal storage disorders. Exp. Opin. Emerg. Drugs 10 (2005) 891-902
84. Sawkar A.R., Cheng W.C., Beutler E., Wong C.H., Balch W.E., and Kelly J.W. Chemical chaperones increase the cellular activity of N370S beta-glucosidase: a therapeutic strategy for Gaucher disease. Proc. Natl. Acad. Sci. USA 99 (2002) 15428-15433
85. Sands M.S., and Davidson B.L. Gene therapy for lysosomal storage diseases. Mol. Ther. 13 (2006) 839-849
86. D'Azzo A. Gene transfer strategies for correction of lysosomal storage disorders. Acta Haematol. 110 (2003) 71-85